Skip to content
zameds

Lansoprazole (Adco-roznal, Burnloc, Covan Lansoprazole, Roznal Otc, Sabax Lansoprazole)

Lansoprazole

Adcock ingram limited

Registration

Applicant
Adcock ingram limited
Certificate holder
Adcock ingram limited
Registrations
5

Variants

ProductStrength and formRegistrationStatusScheduleLeaflets
Adco-roznal

EACH CAPSULE CONTAINS : LANSOPRAZOLE 30,0 mg

30 mgCapsules37055837/11.4.3/0558Approved 15 January 2021RegisteredNot determinedPIPIL
Burnloc

EACH CAPSULE CONTAINS LANSOPRAZOLE 15,0 mg

15mgCapsuleA390116A39/11.4.3/0116Approved 26 March 2025RegisteredNot determinedPIPIL
Covan lansoprazole 15

EACH CAPSULE CONTAINS LANSOPRAZOLE 15,0 mg

15A400153A40/11.4.3/0153CancelledNot determinedNone
Roznal otc

EACH CAPSULE CONTAINS LANSOPRAZOLE 15,0 mg

Not listedA400154A40/11.4.3/0154RegisteredNot determinedNone
Sabax lansoprazole 15 MG

EACH CAPSULE CONTAINS LANSOPRAZOLE 15,0 mg

15 mgA400155A40/11.4.3/0155CancelledNot determinedNone

Regulatory status

This product is still scheduled by law even when this site could not determine which tier it falls under. The label carries the S number in a square border; ask a pharmacist if you need to know its schedule.

Listings for this ingredient that could not be applied to this product

  • S4: Lansoprazole

    • except when intended for the temporary short-term relief of heartburn and hyperacidity, subject to:
    • a maximum daily dose of 15 milligrams (S2); and
    • a maximum treatment period of 14 days. (S2)

    Consolidated Schedules 06 July 2026, lines 6854 to 6857

  • S2: Lansoprazole

    • when intended for the temporary short-term relief of heartburn and hyperacidity, subject to –
    • maximum daily dose of 15 milligrams
    • maximum treatment period of 14 days. (S4)

    Consolidated Schedules 06 July 2026, lines 2224 to 2228

This is an informational summary of the Medicines and Related Substances Act 101 of 1965 and its 2017 General Regulations. It is not medical advice and not legal advice. Always check the medicine's label, which carries the schedule number inside a square border, or ask a pharmacist if you are unsure.

C16H14F3N3O2S369.40 g/mol

2-[[3-Methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methylsulfinyl]-1H-benzimidazole

Drag to rotate. Structure from PubChem CID 3883.

SAHPRA documents

These documents are provided by SAHPRA for informational purposes. Always consult with a healthcare professional for medical advice.

Background

Loading...
Loading Wikipedia summary

Research articles

Loading...
Loading PubMed articles